Results of autologous transplantation for @entity1582 ( XXXX ) in Austria. An analysis based on data from the Austrian Stem Cell Transplantation (ASCT) Registry.

@entity1582 @entity1 @entity348
UNASSIGNED: 6657 Background: Median survival with conventional therapy in @entity1582 is usually less than 40 months. Two prospective randomised trials (IFM 90 and MRC trial) showed superiority of high-dose therapy with autologous SCT over conventional treatment, although other trials were unable to confirm a statistical significant benefit. Here we report the results of high dose chemotherapy in all @entity1 (> 99.5%) with @entity1582 treated in Austria. METHODS: 324 @entity1 treated with autologous SCT from 1989 onwards have retrospectively been analysed. Median age: 55.6 years (range 24.6 -70.7 years). Peripheral blood stem cells were used in 317 and bone-marrow derived stem cells in 7 @entity1 . 170 @entity1 were treated with single (ST) and 98 with double transplantation (DT), while all other @entity1 received >2 autografts during the whole course of their disease. The influence of @entity348 ( @entity348 ) and interferon (IFN) maintenance was also analysed. All but one @entity1 were evaluable for survival, and 265 @entity1 were evaluable for response. RESULTS: A CR (without proof of negative immunofixation) was achieved in 37% and a PR in 53% of @entity1 ( OR 90% ). TRM was 2.5% at 3 months, and median survival 66.5 months at a median follow-up of 14.2 months. DT yielded a significantly longer overall survival as compared to ST (p< 0.05; survival at 1 year 86% vs. 71%, respectively). There was a tendency for a shorter survival in @entity1 with @entity348 as compared to those without @entity348 (survival 51 months vs. not reached, p=n.s.). Preliminary analysis shows significant prolongation of maintenance duration and survival with IFN maintenance treatment, but final analysis of a matched pair analysis will be presented. CONCLUSIONS: High dose chemotherapy with autologous SCT revealed a favourable survival (66.5 months) in @entity1 with @entity1582 of which only a minority have been treated in clinical trials in Austria. DT was associated with a significantly longer survival, while use of @entity348 was associated with a tendency towards shorter survival. Preliminary data suggest beneficial effects of IFN on maintenance duration and on survival. No significant financial relationships to disclose.
